Фундаментальные открытия и регистрационные клинические исследованияDe Lecea L., Kilduff T.S. et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. PNAS. 1998.
DOI 10.1073/pnas.95.1.322.
Sakurai T., Amemiya A., Ishii M. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998.
DOI 10.1016/S0092-8674(00)80949-6.
Lin L., Faraco J. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999.
DOI 10.1016/S0092-8674(00)81965-0.
Chemelli R.M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999.
DOI 10.1016/S0092-8674(00)81973-X.
Brisbare-Roch C. et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nature Medicine. 2007.
DOI 10.1038/nm1544.
Herring W.J. et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biological Psychiatry. 2016.
DOI 10.1016/j.biopsych.2014.10.003.
Rosenberg R. et al. Comparison of lemborexant with placebo and zolpidem extended release in older adults with insomnia disorder. JAMA Network Open. 2019.
PMID 31880796.
Kärppä M. et al. Efficacy and safety of lemborexant in adults with insomnia disorder: results from the phase 3 SUNRISE 2 trial. Sleep. 2020.
PMID 32585700.
Mignot E. et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurology. 2022.
DOI 10.1016/S1474-4422(21)00436-1.
Lucey B.P. et al. Suvorexant acutely decreases tau phosphorylation and Aβ in the human central nervous system. Annals of Neurology. 2023.
DOI 10.1002/ana.26641.
Новые исследования 2025–2026 годов и реальная клиническая практикаKishi T. et al. Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. Translational Psychiatry. 2025.
DOI 10.1038/s41398-025-03439-8.
Efficacy and safety of seltorexant in insomnia disorder: a randomized clinical trial. JAMA Psychiatry. 2025.
DOI 10.1001/jamapsychiatry.2025.1999.
Effect of daridorexant on nighttime wakefulness and next-morning sleepiness. Sleep Medicine. 2025.
DOI 10.1016/j.sleep.2025.106523.
A randomised crossover trial of daridorexant for the treatment of chronic insomnia and nocturia. 2025.
PMID 40083090.
Mishima K. et al. Safety and efficacy of lemborexant: post-marketing observational study. 2024.
PMID 38839690.
Sun Y. et al. Safety of dual orexin receptor antagonists: a real-world pharmacovigilance study. Expert Opinion on Drug Safety. 2025.
DOI 10.1080/14740338.2025.2471520.
Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study. Sleep. 2026.
DOI 10.1093/sleep/zsaf291.
Dauvilliers Y. et al. Oveporexton for narcolepsy type 1: results from two phase 3 trials. NEJM. 2026.
DOI 10.1056/NEJMoa2601598.
Plazzi G. et al. Safety, tolerability, and efficacy of alixorexton for narcolepsy type 1 (Vibrance-1). Lancet Neurology. 2026.
DOI 10.1016/S1474-4422(26)00278-4.
Rollo E. et al. Treatment of chronic insomnia in elderly adults with dual orexin receptor antagonists: a systematic review and meta-analysis. Sleep. 2026.
DOI 10.1093/sleep/zsag135.
Dose-response meta-analysis of dual orexin receptor antagonists on sleep parameters and implications for orexin-mediated arousal. Sleep Medicine. 2026.
DOI 10.1016/j.sleep.2026.109249.
Use of dual orexin receptor antagonists for insomnia and the risk of falls and fractures: a systematic review and meta-analysis. J Am Geriatr Soc. 2026.
DOI 10.1111/jgs.70745.
Liu T.H. et al. Risk of falls and delirium associated with DORA versus benzodiazepines/Z-drugs. Translational Psychiatry. 2026.
DOI 10.1038/s41398-026-04394-8.
Bidirectional neuro-immune interactions of the orexin/hypocretin system. Systematic review. 2026.
DOI 10.1111/cen3.70078.
Guo J. et al. Orexin-A attenuates the inflammatory response in sepsis-associated encephalopathy by modulating oxidative stress and inhibiting the ERK/NF-κB signaling pathway in microglia and astrocytes. CNS Neuroscience & Therapeutics. 2024.
DOI 10.1111/cns.70096.
Chen Y. et al. Orexin A alleviates chronic cerebral hypoperfusion-induced neuroinflammation and cognitive dysfunction by inhibiting the NEK7/NLRP3 pathway. Experimental Neurology. 2025.
DOI 10.1016/j.expneurol.2025.115378.
Ebrahimi M.S. et al. Orexin-A and BDNF in the hippocampus of middle-aged rats: beneficial effects of integrating voluntary physical activity with intermittent fasting. Physiology & Behavior. 2025.
DOI 10.1016/j.physbeh.2025.115009.
Yu Y. et al. Mitigation of learning and memory impairment caused by acute total sleep deprivation through OX1R/OX2R-mediated hippocampal neurogenesis in rats. Experimental Gerontology. 2025.
DOI 10.1016/j.exger.2025.112769.
Diurnal inhibition of NMDA-EPSCs at rat hippocampal mossy fibre synapses through orexin-2 receptors. The Journal of Physiology. 2014.
DOI 10.1113/jphysiol.2014.272757.
McElroy S.L. et al. Nivasorexant in binge-eating disorder: randomized phase 2 trial. Int J Eat Disord. 2023.
DOI 10.1002/eat.24039.
Tebideutorexant as adjunctive treatment of depression with anxious distress: randomized phase 2a trial. Eur Neuropsychopharmacol. 2025.
DOI 10.1016/j.euroneuro.2025.03.007.
Targeting the orexin system in the pharmacological management of insomnia and other diseases: suvorexant, lemborexant, daridorexant, and novel experimental agents. Int J Mol Sci. 2025;26(17):8700.
DOI 10.3390/ijms26178700.
The effect of dual orexin receptor antagonists on sleep: a systematic review and pairwise meta-analysis. Sleep Medicine. 2026.
DOI 10.1016/j.sleep.2026.108792.
Long-term use of dual orexin receptor antagonists for the treatment of insomnia: a systematic review and meta-analysis. 2026.
DOI 10.1055/s-0046-1827049.
Spiegelhalder K., Baglioni C., Morin C.M. et al. Insomnia disorder. Nature Reviews Disease Primers. 2026;12:17.
DOI 10.1038/s41572-026-00693-y.
Российские публикацииПолуэктов М.Г., Ляшенко Е.А., Бабак С.Л. и соавт. Лемборексант: новые горизонты в терапии инсомнии. Эффективная фармакотерапия. 2026;22(27):26–36.
DOI 10.33978/2307-3586-2026-22-27-26-36.
Кичерова О.А., Тищенко А.В., Кичерова К.П. и соавт. Нейроциркадные и гомеостатические механизмы регуляции сна: взаимодействие вентролатерального преоптического ядра с орексинергической системой. 2026.
DOI 10.17816/clinpract706200.
Яковлева О.В., Полуэктов М.Г., Бузунов Р.В. и соавт. Проект клинических рекомендаций по диагностике и лечению острой и хронической инсомнии у взрослых. Эффективная фармакотерапия. 2025;21(37):20–34.
DOI 10.33978/2307-3586-2025-21-37-20-34.
- Тихомирова О.В. Стресс и сон: нейробиологические аспекты и современные возможности терапии инсомнии. Журнал неврологии и психиатрии им. С. С. Корсакова. 2025;125(5-2):14–21. DOI 10.17116/jnevro202512505214.